The ABCD Nationwide Audit3 explored the real-world experiences of FreeStyle Libre users in the UK and the impact on glycaemic control.
From baseline 67.5 mmol/mol HbA1c across the entire study population
from 13.7% to 4.7% at 12 months
A RWE study of the effect of the FreeStyle Libre 2 system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes.
(p=0.005)
from 3.3% to 2.2% at 12 months
A RWE study of the effect of the FreeStyle Libre 2 system on 1913 T1D patients at 6 months and 1 year: endpoints included quality of life, number of hospital admissions, and hypoglycaemia.
(p=0.0031)
from 18.5% to 7.7% at 12 months
Real world data showed that work absenteeism in patients <65 years was decreased by 60% in patients using a FreeStyle Libre system (from 20.4% to 8.3%; p<0.001).
A RWE study of the effect of the FreeStyle Libre system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes.
(p=0.001)
Clinical benefits for a broad range of T1D and T2D patients.
Explore our training resources to help you to help your patients understand Time in Range better.
Learn more about Time in Range and the FreeStyle Libre system through our Healthcare Professional education modules.
We offer various on-demand webinars for Healthcare Professionals including Understanding Time in Range.
Learn more about Time in Range in our CME accredited three-module webcast series.
References & Disclaimers
Images are for illustrative purposes only. Not real patient, data or healthcare professional.
* FreeStyle Libre systems refers to the FreeStyle Libre 2 and FreeStyle Libre 3 systems.
◊ The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink may require registration with LibreView.
1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.
2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.
3. Deshmukh H, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.
4. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.
5. Kao K., Journal of Diabetes Science and Technology. (2021): https://doi.org/10.1177%2F19322968211044141.
6. Battelino T., Diabetes Care. (2019): https://doi.org/10.2337/dci19-0028
7. Charleer, S. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610.
The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.
Do you want to leave this page?
If you're a healthcare professional located in a different country, please select your country's website from the list of our global sites or contact your local Abbott representative for correct information about the products available in your country.
If you're not a healthcare profressional, click here to go to the FreeStyle Libre consumer website for the UK.
Stay connected